Northcoast Research Reiterates “Buy” Rating for Align Technology, Inc. (ALGN)

Align Technology, Inc. (NASDAQ:ALGN)‘s stock had its “buy” rating reiterated by research analysts at Northcoast Research in a research report issued on Tuesday. They presently have a $230.00 price objective on the medical equipment provider’s stock, up from their previous price objective of $200.00. Northcoast Research’s price target points to a potential upside of 19.51% from the stock’s previous close. Northcoast Research also issued estimates for Align Technology’s Q3 2017 earnings at $0.82 EPS, FY2017 earnings at $3.42 EPS, Q2 2018 earnings at $1.14 EPS and Q3 2018 earnings at $1.15 EPS.

ALGN has been the subject of several other reports. Bank of America Corporation raised shares of Align Technology from a “neutral” rating to a “buy” rating and upped their price objective for the company from $175.00 to $193.00 in a research note on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and set a $205.00 price target (up previously from $200.00) on shares of Align Technology in a research report on Monday, August 7th. Robert W. Baird reiterated a “buy” rating on shares of Align Technology in a research report on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) boosted their price target on shares of Align Technology from $185.00 to $210.00 and gave the company a “buy” rating in a research report on Friday, September 15th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $220.00 price target (up previously from $195.00) on shares of Align Technology in a research report on Friday, October 6th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $193.20.

Shares of Align Technology (NASDAQ ALGN) opened at 192.46 on Tuesday. Align Technology has a one year low of $83.27 and a one year high of $193.19. The firm has a market capitalization of $15.43 billion, a P/E ratio of 65.91 and a beta of 1.54. The firm’s 50-day moving average price is $182.92 and its 200-day moving average price is $153.98.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, beating the consensus estimate of $0.73 by $0.12. The firm had revenue of $356.50 million during the quarter, compared to the consensus estimate of $343.43 million. Align Technology had a net margin of 19.18% and a return on equity of 23.87%. The company’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.62 earnings per share. On average, equities analysts forecast that Align Technology will post $3.41 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/10/12/northcoast-research-reiterates-buy-rating-for-align-technology-inc-algn.html.

Large investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. purchased a new stake in shares of Align Technology during the second quarter valued at approximately $1,768,000. AQR Capital Management LLC grew its holdings in shares of Align Technology by 36.7% during the first quarter. AQR Capital Management LLC now owns 94,715 shares of the medical equipment provider’s stock valued at $10,865,000 after buying an additional 25,422 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Align Technology by 2,236.0% during the second quarter. American Century Companies Inc. now owns 221,009 shares of the medical equipment provider’s stock valued at $33,178,000 after buying an additional 211,548 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its holdings in shares of Align Technology by 17.8% during the second quarter. Robeco Institutional Asset Management B.V. now owns 90,969 shares of the medical equipment provider’s stock valued at $13,657,000 after buying an additional 13,753 shares during the last quarter. Finally, Chevy Chase Trust Holdings Inc. purchased a new stake in shares of Align Technology during the second quarter valued at approximately $9,854,000. Hedge funds and other institutional investors own 81.56% of the company’s stock.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply